TuHURA Biosciences Inc HURA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
-
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
-
TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
-
TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
-
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
-
TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
-
These 16 stocks are a short seller's dream - likely losers no matter what the market does
Trading Information
- Previous Close Price
- $1.83
- Day Range
- $1.76–1.85
- 52-Week Range
- $0.41–3.43
- Bid/Ask
- $1.76 / $1.98
- Shares Outstanding
- 63.73M
- Market Cap
- $112.16M
- Volume/Avg
- 86,042 / 225,204
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 22
- Website
- https://www.tuhurabio.com
Valuation
|
Metric
|
HURA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.15 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
HURA
|
|---|---|
Quick Ratio | 0.11 |
Current Ratio | 0.18 |
Interest Coverage | −26.35 |
Quick Ratio
HURA
Profitability
|
Metric
|
HURA
|
|---|---|
Return on Assets (Normalized) | −61.11% |
Return on Equity (Normalized) | −93.51% |
Return on Invested Capital (Normalized) | −77.69% |
Return on Assets
HURA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|WHf&#&V | LOCK|v%%Rm | $127B | |||
| Moderna Inc
MRNA
| LOCK|S##YX# | LOCK|C< | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|N>!B%& | LOCK|&XYY# | $81B | |||
| argenx SE ADR
ARGX
| LOCK|xh&<<y | LOCK|GX | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$cxgy> | LOCK|Mk | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Yp%?PK# | LOCK|>m@y | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?bs^qsZ | LOCK|Bd<F | $27B | |||
| Incyte Corp
INCY
| LOCK|b!<r%%S | LOCK|p!$ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Z?C>w!b | LOCK|^$ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&<zVFjs | LOCK|&Xc | $14B |
United States